Profound Medical Corp. reported its financial results for the second quarter and first half of 2026, revealing a significant increase in revenue and a reduction in net losses compared to the same periods in 2025. For the three months ended June 30, 2026, the company generated revenue of $2.48 million, a 12% increase from $2.21 million in the prior year. For the six-month period, revenue reached $7.82 million, up 62% from $4.83 million in 2025. The growth was attributed to higher sales of capital equipment and increased recurring revenue from one-time-use devices.

The company's operating expenses also decreased, with total operating expenses for the second quarter falling to $13.01 million from $15.42 million in the same quarter last year. This reduction was driven by lower selling, general, and administrative expenses, which decreased by 21% to $7.36 million. Research and development expenses remained relatively stable, totaling $5.65 million for the quarter. As a result, Profound Medical reported a net loss of $9.54 million for the second quarter, down from $15.70 million in the same period last year, reflecting a 39% improvement.

In terms of operational metrics, Profound Medical's customer engagement appears to be on the rise, with the company focusing on the commercialization of its TULSA-PRO system and Sonalleve platform. The TULSA-PRO system, which utilizes MRI-guided technology for prostate tissue ablation, is gaining traction in the market, supported by its CE mark and FDA clearance. The company is also exploring additional treatment markets for Sonalleve, which is already approved for uterine fibroids and palliative pain treatment.

As of June 30, 2026, Profound Medical's cash reserves stood at $38.27 million, a decrease from $59.72 million at the end of 2025. The company anticipates that its existing cash and product sales will be sufficient to fund operations for at least the next 12 months. However, it acknowledges the potential need for additional capital to support ongoing research and development and to expand operations. The company remains committed to enhancing its product offerings and increasing market share in the medical device sector, particularly in the areas of prostate and uterine treatments.

About Profound Medical Corp.

Profound Medical develops MRI-guided, incision-free therapeutic systems for minimally invasive ablation of diseased tissue, primarily targeting prostate conditions and uterine fibroids. Its flagship products, TULSA-PRO and Sonalleve, utilize real-time MRI, focused ultrasound, and thermal feedback to deliver precise, customizable treatments. Serving global markets, the company offers solutions that aim to improve clinical outcomes, reduce side effects, and enable outpatient procedures in urology and gynecology.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov